Xin Xu, PhD, MS, M(ASCP)
- Cancer and Blood Disorders
Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
Office locations:
Texas Medical Center
6701 Fannin Street
Houston, TX 77030
Get to know Xin Xu, PhD, MS, M(ASCP)
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Baylor College of Medicine | Post-doctoral Fellowship | Microbiology and Cell Biology | 2018 |
| Universität Osnabrück | PhD | Doctor of Philosophy, Microbiology | 2014 |
| North East Normal University | Masters | Master of Science, Biochemistry and Molecular Biology | 2004 |
Organizations
| Organization Name | Role |
|---|---|
| American Association of Immunologists (AAI) | Member |
| American Society of Gene and Cell Therapy (ASGCT) | Member |
Honors and awards
- 2018
-
AAI Trainee Award and oral presentation, American Association of Immunologists (AAI)
- 2017
-
20th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
- 2014
-
Texas Children’s Cancer and Hematology Center, 10th Annual Research Symposium
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Research Area:
Center for Advanced Innate Cell Therapy
Lymphoma
Neuroblastoma
Dr. Xin Xu is a formally-trained microbiologist with extensive experience in translational research. His postdoctoral research focused on development of an innovative salmonella-based cancer vaccine platform that is currently being submitted as the subject of an Investigational New Drug (IND) application with the goal of clinical evaluation.
His pre-clinical work showed that the vaccine induces potent anti-tumor activity and long-term protective immune memory in mice (Xu et al., Cancer Research). These studies have been awarded with highly competitive grants from The Cancer Prevention and Research Institute of Texas (CPRIT), the Leukemia & Lymphoma Society, and the V Foundation and led to IND submission for phase 1 clinical trial of a salmonella-based cancer vaccine in patients with multiple myeloma.
Within the Metelitsa group, he has conducted correlative studies on patient samples from our recently initiated first-in-human CAR NKT cell clinical trial in children with neuroblastoma (NCT03294954). He is also exploring translational methods to improve the persistence and efficacy of CAR NKT immunotherapy.
Certifications
Technologist in Microbiology
American Society for Clinical Pathology (ASCP)
Professional Interests
CAR T/NKT cell therapy
Cancer vaccine
Pediatric solid tumors
Natural Killer T (iNKT) cell biology
